We recently published a list of 10 Most Undervalued S&P 500 Stocks to Buy Now. In this article, we are going to take a look ...

“Due to significant reductions in demand for these products, the company has decided to cease operations at the plant,” the ...

The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...

With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...

Evaluate, the leading provider of market insights for the pharmaceutical industry, today released its 2025 Orphan Drug Report highlighting forecasts for the orphan drug market out to 2030. The 2025 ...

Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff wars, hoping to avert price spikes on top-selling medicines made in Europe ...

The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors�reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...

Merck & Co Inc. has become a top contender for the most profitable value stock, but it faces some challenges. Merck boasts a forward P/E ratio of 10.36 and TTM net income of $17.117 billion. Despite ...

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft sales ...

Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ETCompany ParticipantsKurt Gustafson - Chief Financial OfficerMatt ...

In re: Xencor, Inc., Appeal No. 2024-1870 (Fed. Cir. Mar. 13, 2025) ...